These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12939814)

  • 1. [Correlation between tumor necrosis factor alpha and matrix metalloproteinases levels in serum of patients with rheumatic arthritis].
    Klimiuk PA; Sierakowski S; Chwiećko J
    Pol Merkur Lekarski; 2003 May; 14(83):410-2. PubMed ID: 12939814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
    Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
    J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
    Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
    J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinases MMP-3 and MMP-1 levels in sera and synovial fluids in patients with rheumatoid arthritis and osteoarthritis.
    Mahmoud RK; El-Ansary AK; El-Eishi HH; Kamal HM; El-Saeed NH
    Ital J Biochem; 2005; 54(3-4):248-57. PubMed ID: 16688934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis.
    Fiedorczyk M; Klimiuk PA; Sierakowski S; Gindzienska-Sieskiewicz E; Chwiecko J
    J Rheumatol; 2006 Aug; 33(8):1523-9. PubMed ID: 16881109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy.
    Vandooren B; Kruithof E; Yu DT; Rihl M; Gu J; De Rycke L; Van Den Bosch F; Veys EM; De Keyser F; Baeten D
    Arthritis Rheum; 2004 Sep; 50(9):2942-53. PubMed ID: 15457463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Correlations between serum matrix metalloproteinase (MMP-1, MMP-3, MMP-9, MMP-13) concentrations and markers of disease activity in early rheumatoid arthritis].
    Fiedorczyk M; Klimiuk PA; Sierakowski S; Domysławska I; Chwiećko J
    Przegl Lek; 2005; 62(12):1321-4. PubMed ID: 16786739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Serum tumor necrosis factor alpha (TNF-alpha) concentration correlates with soluble adhesion molecules and vascular endothelial growth factor (VEGF) in rheumatoid arthritis].
    Klimiuk PA; Sierakowski S; Fiedorczyk M; Chwiećko J
    Przegl Lek; 2004; 61(2):86-9. PubMed ID: 15230147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production of matrix metalloproteinases and their inhibitors in osteoarthritic patients undergoing mud bath therapy.
    Bellometti S; Richelmi P; Tassoni T; Bertè F
    Int J Clin Pharmacol Res; 2005; 25(2):77-94. PubMed ID: 16060398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis.
    Ishiguro N; Ito T; Obata K; Fujimoto N; Iwata H
    J Rheumatol; 1996 Sep; 23(9):1599-604. PubMed ID: 8877931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Serum interleukin 6 (il-6A) concentration correlates with matrix metalloproteinases and their tissue inhibitors in rheumatoid arthritis].
    Klimiuk PA; Sierakowski S; Chwiećko J
    Pol Arch Med Wewn; 2003 Feb; 109(2):119-23. PubMed ID: 12879774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure.
    Wilson EM; Gunasinghe HR; Coker ML; Sprunger P; Lee-Jackson D; Bozkurt B; Deswal A; Mann DL; Spinale FG
    J Card Fail; 2002 Dec; 8(6):390-8. PubMed ID: 12528092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
    Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ
    Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokines regulate matrix metalloproteinases in human uterine endometrial fibroblast cells through a mechanism that does not involve increases in extracellular matrix metalloproteinase inducer.
    Braundmeier AG; Nowak RA
    Am J Reprod Immunol; 2006 Sep; 56(3):201-14. PubMed ID: 16911716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.
    Chen CH; Lin KC; Yu DT; Yang C; Huang F; Chen HA; Liang TH; Liao HT; Tsai CY; Wei JC; Chou CT
    Rheumatology (Oxford); 2006 Apr; 45(4):414-20. PubMed ID: 16287916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of 1, 25 dihydroxyvitamin D(3) on matrix metalloproteinases MMP-7, MMP-9 and the inhibitor TIMP-1 in pulmonary tuberculosis.
    Anand SP; Selvaraj P
    Clin Immunol; 2009 Oct; 133(1):126-31. PubMed ID: 19615945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leflunomide and methotrexate reduce levels of activated matrix metalloproteinases in complexes with alpha2 macroglobulin in serum of rheumatoid arthritis patients.
    Tchetverikov I; Kraan MC; van El B; Hanemaaijer R; DeGroot J; Huizinga TW
    Ann Rheum Dis; 2008 Jan; 67(1):128-30. PubMed ID: 17875551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pro-inflammatory cytokine, matrix metalloproteinases and TIMP-1 are involved in wound healing after mastectomy in invasive breast cancer patients.
    Loo WT; Sasano H; Chow LW
    Biomed Pharmacother; 2007 Oct; 61(9):548-52. PubMed ID: 17904786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased level of cytokines and matrix metalloproteinases in osteoarthritic subchondral bone.
    Hulejová H; Baresová V; Klézl Z; Polanská M; Adam M; Senolt L
    Cytokine; 2007 Jun; 38(3):151-6. PubMed ID: 17689092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor necrosis factor alpha, its soluble receptor I, and -308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis: implications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis.
    Maury CP; Liljeström M; Laiho K; Tiitinen S; Kaarela K; Hurme M
    Arthritis Rheum; 2003 Nov; 48(11):3068-76. PubMed ID: 14613268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.